SCHEMBL2762771

SCHEMBL2762771

CC(=O)Nc1ccc(-c2csc(NS(=O)(=O)c3c(Cl)cc(Cl)cc3Cl)n2)cc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.63
ABL1 P00519 6/20 0.58
KMT2A Q03164 6/20 0.58
GAA P10253 2/20 0.58
GFER P55789 1/20 0.58
MEN1 O00255 5/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
KDM4E B2RXH2 1/20 0.57
STAT3 P40763 1/20 0.57
ALDH1A1 P00352 3/20 0.56
LMNA P02545 2/20 0.55
MAPK1 P28482 2/20 0.55
HTT P42858 1/20 0.55
KDM1A O60341 5/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MAOA P21397 2/20 0.52
PKM P14618 1/20 0.52
SIRT5 Q9NXA8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762675 0.94 MAPT (0.59) MAPTABL1KMT2AGAAGFER
SCHEMBL2763208 0.90 MAPT (0.64) MAPTABL1KMT2AGAAGFER
SCHEMBL2762593 0.86 MAPT (0.65) MAPTABL1KMT2AGAAGFER
SCHEMBL5831228 0.83 MEN1 (0.59) MAPTABL1KMT2AGAAMEN1
SCHEMBL27572746 0.82 KMT2A (0.52) MAPTABL1KMT2AGAAGFER
SCHEMBL27572745 0.82 MAPT (0.51) MAPTABL1KMT2AGAAGFER
SCHEMBL5831178 0.81 ATM (0.51) MAPTKMT2AGAAMEN1SMN1; SMN2
SCHEMBL2762584 0.81 MEN1 (0.72) KMT2AMEN1KDM1AMAOA
SCHEMBL2762767 0.81 MAPT (0.62) MAPTABL1KMT2AGAAGFER
SCHEMBL2762554 0.81 KDM1A (0.73) MAPTABL1KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP claimed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US claimed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO claimed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US claimed
EP-1283832-B1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2010-10-20 EP disclosed
US-7132436-B2 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-11-07 US disclosed
WO-2004112783-A1 NEW USE IV BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 CLARIO TECH LIMITED (GB) 2003-09-04 US disclosed
EP-1283832-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 EP disclosed
WO-2001090092-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166689-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 MAPT 3275/4885ABL1 3847/4885KMT2A 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.